Limitations of non-invasive tests for assessment of liver fibrosis
Explore this paper's citation graph
Summary
Understanding the strengths and limitations of these non-invasive tests will allow for more judicious interpretation in the clinical context, where NITs should be viewed as complementary to, rather than as a replacement for, liver biopsy.
- Type
- review
- Published
- 2020-01-20
- Cited by
- 297
- References
- 152
- Access
- Open access
- OpenAlex
- https://openalex.org/W3002581322
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:211563295
Keywords
Medicine, Liver biopsy, Steatohepatitis, Context (archaeology), Fibrosis
References
- Progression of fibrosis in advanced chronic hepatitis C: Evaluation by morphometric image analysis
- Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions.
- Chronic hepatitis C infection - Noninvasive assessment of liver fibrosis in the era of direct acting antivirals.
- Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings
- EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.
- Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.
- Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population
- qFibrosis: A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients
- Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C
- A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers
- Utility of Magnetic Resonance Imaging Versus Histology for Quantifying Changes in Liver Fat in Nonalcoholic Fatty Liver Disease Trials
- Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
- Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
- Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT.
- Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C.
- Serum Fibrosis Marker Levels Decrease After Successful Antiviral Treatment in Chronic Hepatitis C Patients with Advanced Fibrosis
- Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs
- An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa‐2b combination therapy for chronic hepatitis C
- Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis.
- FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice.
Cited by
- Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials
- Development and validation of a transcriptional signature for the assessment of fibrosis in organs
- The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
- Elucidating Potential Profibrotic Mechanisms of Emerging Biomarkers for Early Prognosis of Hepatic Fibrosis
- Noninvasive diagnostic tools for pediatric NAFLD: where are we now?
- Effect of COVID-19 on patients with compensated chronic liver diseases
- Utility of Mac‐2 Binding Protein Glycosylation Isomer to Evaluate Graft Status After Liver Transplantation
- For fatty liver diseases, it is time to utilize non-invasive fibrosis tests to predict liver related events rather than just histological stages of hepatic fibrosis!
- Advances in the clinical use of collagen as biomarker of liver fibrosis
- Non-alcoholic fatty liver disease and transient elastography
- The Impact of Non-alcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective.
- Applying Machine Learning to Evaluate for Fibrosis in Chronic Hepatitis C
- Longitudinal decrease in platelet counts as a surrogate marker of liver fibrosis
- Genetic Susceptibility and Protein Expression of Extracellular Matrix Turnover-Related Genes in Oral Submucous Fibrosis
- Biomarkers for Liver Fibrosis Post–Liver Transplantation: Not As Easy As It Looks
- Letter: the use of Fibrosis‐4 score in primary care and diabetology practices—Occam’s razor applied to advanced fibrosis screening
- Pathogenesis of Viral Hepatitis-Induced Chronic Liver Disease: Role of Extracellular Vesicles
- Leberspezifische Diagnostik bei der nichtalkoholischen Fettlebererkrankung (NAFLD) – wann kann die Leberbiopsie ersetzt werden?
- Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection
- Novel high-throughput applications for NAFLD diagnostics and biomarker discovery
Related papers
- Review article: is non‐alcoholic fatty liver disease a spectrum, or are steatosis and non‐alcoholic steatohepatitis distinct conditions?
- Manifestation of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Different Dietary Mouse Models
- Categorization and complication of non-alcoholic fatty liver disease
- Practical approach to non‐alcoholic fatty liver disease in patients with diabetes
- Evaluation and management of non-alcoholic steatohepatitis.
- Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research
- Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non- Alcoholic Steatohepatitis.
- Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease
- Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis.
- Non-Alcoholic Fatty Liver Disease in Children